KR20180008571A - 다발성 골수종(mm)의 치료 - Google Patents

다발성 골수종(mm)의 치료 Download PDF

Info

Publication number
KR20180008571A
KR20180008571A KR1020177035726A KR20177035726A KR20180008571A KR 20180008571 A KR20180008571 A KR 20180008571A KR 1020177035726 A KR1020177035726 A KR 1020177035726A KR 20177035726 A KR20177035726 A KR 20177035726A KR 20180008571 A KR20180008571 A KR 20180008571A
Authority
KR
South Korea
Prior art keywords
antibody
administered
sequence
ser
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177035726A
Other languages
English (en)
Korean (ko)
Inventor
스테파니 레클레어
잔 엔델
스테판 하틀
Original Assignee
모르포시스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모르포시스 아게 filed Critical 모르포시스 아게
Publication of KR20180008571A publication Critical patent/KR20180008571A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
KR1020177035726A 2015-05-13 2016-05-13 다발성 골수종(mm)의 치료 Ceased KR20180008571A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15167597.2 2015-05-13
EP15167597 2015-05-13
PCT/EP2016/060810 WO2016180958A1 (en) 2015-05-13 2016-05-13 Treatment for multiple myeloma (mm)

Publications (1)

Publication Number Publication Date
KR20180008571A true KR20180008571A (ko) 2018-01-24

Family

ID=53174925

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177035726A Ceased KR20180008571A (ko) 2015-05-13 2016-05-13 다발성 골수종(mm)의 치료

Country Status (24)

Country Link
US (2) US10533057B2 (https=)
EP (1) EP3294769B1 (https=)
JP (2) JP7160533B2 (https=)
KR (1) KR20180008571A (https=)
CN (1) CN107614530A (https=)
AU (1) AU2016260895B2 (https=)
CA (1) CA2984464C (https=)
CY (1) CY1123982T1 (https=)
DK (1) DK3294769T3 (https=)
ES (1) ES2862708T3 (https=)
HR (1) HRP20210552T1 (https=)
HU (1) HUE054271T2 (https=)
IL (1) IL255552B (https=)
LT (1) LT3294769T (https=)
MX (1) MX380557B (https=)
PL (1) PL3294769T3 (https=)
PT (1) PT3294769T (https=)
RS (1) RS61668B1 (https=)
RU (1) RU2723047C2 (https=)
SG (1) SG11201708691VA (https=)
SI (1) SI3294769T1 (https=)
SM (1) SMT202100202T1 (https=)
WO (1) WO2016180958A1 (https=)
ZA (1) ZA201708386B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
PT3294769T (pt) * 2015-05-13 2021-04-13 Morphosys Ag Tratamento para mieloma múltiplo (mm)
MA45674A (fr) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
KR20210006321A (ko) 2018-01-12 2021-01-18 다케다 야쿠힌 고교 가부시키가이샤 항-cd38 항체의 피하 투여
CN110144008B (zh) * 2018-02-12 2021-03-19 杭州尚健生物技术有限公司 Cd38蛋白抗体及其应用
BR112020019710A2 (pt) * 2018-03-28 2021-01-26 Takeda Pharmaceutical Company Limited métodos para tratar uma doença em um sujeito e para tratar um câncer hematológico em um sujeito, e, forma farmacêutica unitária.
CN109265551B (zh) * 2018-09-25 2020-09-15 华东师范大学 Cd38抗体、嵌合抗原受体和药物
CN113194925B (zh) * 2018-12-14 2025-03-07 莫佛塞斯公司 抗体制剂
US11939390B2 (en) * 2019-01-28 2024-03-26 Sanofi-Aventis U.S. Llc Methods of treating multiple myeloma
US20200308296A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
WO1999062526A2 (en) 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
US8263746B2 (en) 2004-02-06 2012-09-11 Morphosys Ag Anti-CD38 human antibodies and uses thereof
DK2511297T3 (en) 2004-02-06 2015-06-15 Morphosys Ag Human anti-CD38 antibodies and their applications
EP2567976B1 (en) 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
EP2860192B1 (en) 2005-10-12 2017-09-27 MorphoSys AG Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
PL2068874T3 (pl) * 2006-08-07 2015-06-30 Abbvie Biotherapeutics Inc Sposoby leczenia szpiczaka mnogiego z użyciem terapii skojarzonych opartych na przeciwciałach anty-cs1
EP3569245A1 (en) * 2006-09-26 2019-11-20 Genmab A/S Combination treatment of cd38-expressing tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
DK2580243T3 (da) * 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
SI2621531T1 (sl) * 2010-09-27 2017-06-30 Morphosys Ag Anti-cd38 protitelo in lenalidomid ali bortezomib za zdravljenje multiplega mieloma in nhl
WO2014089279A1 (en) * 2012-12-05 2014-06-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Rnf41 as a biomarker predicting response to lenalidomide in non-del(5q) mds
CN103421115B (zh) * 2013-09-02 2015-06-03 东南大学 一种cd38纳米抗体及应用
SG10201803288RA (en) * 2013-10-31 2018-05-30 Sanofi Sa Specific anti-cd38 antibodies for treating human cancers
EP3834889A1 (en) 2014-06-16 2021-06-16 Mayo Foundation for Medical Education and Research Treating myelomas
US10617757B2 (en) * 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
MX386886B (es) 2014-09-09 2025-03-12 Janssen Biotech Inc Combinación de anticuerpos anti-cd38 y ácido todo-trans retinoico para usarse en terapias.
PT3294769T (pt) * 2015-05-13 2021-04-13 Morphosys Ag Tratamento para mieloma múltiplo (mm)

Also Published As

Publication number Publication date
AU2016260895B2 (en) 2021-08-05
IL255552B (en) 2022-01-01
US11591406B2 (en) 2023-02-28
ZA201708386B (en) 2019-06-26
DK3294769T3 (da) 2021-03-08
AU2016260895A1 (en) 2017-11-09
WO2016180958A1 (en) 2016-11-17
HRP20210552T1 (hr) 2021-05-14
HUE054271T2 (hu) 2021-08-30
CY1123982T1 (el) 2022-05-27
PT3294769T (pt) 2021-04-13
CA2984464A1 (en) 2016-11-17
EP3294769B1 (en) 2021-01-13
IL255552A (en) 2018-01-31
US10533057B2 (en) 2020-01-14
JP7160533B2 (ja) 2022-10-25
US20190048091A1 (en) 2019-02-14
SI3294769T1 (sl) 2021-07-30
RU2017137496A3 (https=) 2019-06-13
RU2017137496A (ru) 2019-06-13
PL3294769T3 (pl) 2021-07-05
SG11201708691VA (en) 2017-11-29
RU2723047C2 (ru) 2020-06-08
LT3294769T (lt) 2021-04-26
JP2018515513A (ja) 2018-06-14
SMT202100202T1 (it) 2021-05-07
US20200079871A1 (en) 2020-03-12
ES2862708T3 (es) 2021-10-07
CN107614530A (zh) 2018-01-19
CA2984464C (en) 2023-10-10
RS61668B1 (sr) 2021-04-29
MX2017014396A (es) 2018-03-23
MX380557B (es) 2025-03-12
JP2021130668A (ja) 2021-09-09
EP3294769A1 (en) 2018-03-21

Similar Documents

Publication Publication Date Title
AU2018278327B2 (en) Activatable anti-pdl1 antibodies and methods of use thereof
US11591406B2 (en) Treatment for multiple myeloma (MM)
US20230303691A1 (en) Neutralization of inhibitory pathways in lymphocytes
AU2013322806B2 (en) Combinations and uses thereof
JP7384835B2 (ja) Ｃｄ３に特異的な抗体及びその使用
US12570757B2 (en) Antibodies against the poliovirus receptor (PVR) and uses thereof
CN118949031A (zh) 用gm-csf拮抗剂治疗癌症
TW202547859A (zh) 抗人類pd-l1抗體及其用途
US20230416388A1 (en) Treatment of cancer with anti-gitr agonist antibodies
HK1247939A1 (en) Treatment for multiple myeloma (mm)
HK40128870A (zh) 抗人类pd-l1抗体及其用途
HK40058058A (en) Neutralization of inhibitory pathways in lymphocytes
CA3064588A1 (en) Activatable anti-pdl1 antibodies, and methods of use thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171212

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210420

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230710

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230921

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230710

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I